Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Khanh P. Thieu, BS, Harley A. Haynes, MD

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Applying for dermatology residency is difficult and expensive

Kishore L. Jayakumar, BS, Sara S. Samimi, MD

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin.

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis Tsung-Yu Tsai, MD, Yu-Chen Huang, MD Journal.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Treatment of chronic autoimmune urticaria with omalizumab

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized,

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Lip ulceration in an immunocompromised patient

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A. Bernstein, MD, Karin Rosén, MD, Michael Holden, MD, MS, Ahmar Iqbal, MB, BS, MBA, Benjamin L. Trzaskoma, MS, Ming Yang, PhD, Evgeniya N. Antonova, MS, PhD, Thomas Murphy, MD, Mark D. Scarupa, MD, Howard Sofen, MD, Allen Kaplan, MD Journal of the American Academy of Dermatology Volume 78, Issue 4, Pages 793-795 (April 2018) DOI: 10.1016/j.jaad.2017.10.010 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 XTEND-CIU study design. Q4W, Every 4 weeks; UAS7, 7-day Urticaria Activity Score. ∗Patients not meeting the criteria for randomization (eg, because of nonresponse to omalizumab during the open-label treatment period) returned for a final follow-up visit 12 weeks after the week 24 visit, which included assessments for adverse events and patient-reported outcomes. Patients were not required to complete the electronic diary during this 12-week period. †At week 24, patients were randomized 3:2 to omalizumab or placebo. ‡The final 2 weeks of the open-label treatment period were scheduled to occur during weeks 23 and 24. Double-blind randomization was not permitted after day 190 from baseline. §Patient eligibility to transition to open-label omalizumab at the discretion of the investigator was based on investigator-judged clinically significant worsening of their chronic idiopathic urticaria accompanied by a UAS7 of 12 or higher for at least 2 consecutive weeks. Journal of the American Academy of Dermatology 2018 78, 793-795DOI: (10.1016/j.jaad.2017.10.010) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Protocol-defined (7-day Urticaria Activity Score [UAS7] of ≤6) and complete (UAS7 = 0) responders during the 24-week open-label period. Journal of the American Academy of Dermatology 2018 78, 793-795DOI: (10.1016/j.jaad.2017.10.010) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions